{
    "clinical_study": {
        "@rank": "144485", 
        "arm_group": [
            {
                "arm_group_label": "ASP1585 group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "placebo group", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double blind, placebo-controlled multi-center study to examine the\n      efficacy and safety of ASP1585 in chronic kidney disease patients with hyperphosphatemia not\n      on dialysis."
        }, 
        "brief_title": "A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Kidney Disease", 
            "Renal Insufficiency", 
            "Hyperphosphatemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency", 
                "Hyperphosphatemia", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic kidney disease patients (eGFR < 60 mL/min/1.73 m2)\n\n          -  Serum phosphorus measurement \u22674.6 mg/dl, <9.0 mg/dl\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients with gastrointestinal surgery or enterectomy\n\n          -  Patients with severe cardiac diseases\n\n          -  Patients with severe constipation or diarrhea\n\n          -  Patients with a history or complication of malignant tumors\n\n          -  Patients with uncontrolled hypertension\n\n          -  Patients treated with parathyroid intervention within 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01742585", 
            "org_study_id": "1585-CL-0101"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASP1585 group", 
                "description": "oral", 
                "intervention_name": "ASP1585", 
                "intervention_type": "Drug", 
                "other_name": [
                    "LY101", 
                    "AMG223", 
                    "bixalomer"
                ]
            }, 
            {
                "arm_group_label": "placebo group", 
                "description": "oral", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "CKD", 
            "Not on dialysis", 
            "ASP1585", 
            "Bixalomer"
        ], 
        "lastchanged_date": "April 11, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "ASP1585 Phase 3 Randomized Double Blind Placebo-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia Not on Dialysis", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in serum phosphorus level at the end of treatment", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 12 or treatment discontinuation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01742585"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Achievement rate of the target range of serum phosphorus level", 
                "safety_issue": "No", 
                "time_frame": "During 12 week treatment"
            }, 
            {
                "measure": "Time to achieve the target range of serum phosphorus level", 
                "safety_issue": "No", 
                "time_frame": "During 12 week treatment"
            }, 
            {
                "measure": "Time-course changes in serum phosphorus levels", 
                "safety_issue": "No", 
                "time_frame": "During 12 week treatment"
            }, 
            {
                "measure": "Time-course changes in serum calcium levels", 
                "safety_issue": "No", 
                "time_frame": "During 12 week treatment"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, vital signs, labo-tests and 12-lead ECGs", 
                "safety_issue": "No", 
                "time_frame": "During 12 week treatment"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}